A recent study provides more evidence that patients with psoriasis–even mild cases–face a higher risk of major depression, a finding that could lead dermatologists to alert patients with the condition and even screen them for mental health issues.
Researchers presented new data on the use of the fully human IL-17A inhibitor Cosentyx (secukinumab, Novartis) in moderate-to-severe psoriasis, at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, September 28 through October 2, 2016.
Approvals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
Based on available evidence, dermatologists should at least discuss biologic drugs with patients who have moderate-to-severe psoriasis and cardiovascular comorbidities. Clearing the skin may improve cardiovascular disease, says an expert.
Microbial colonization in the development of inflammatory conditions and immune-mediated conditions is a hot research topic, and new dermatologic therapies can potentially result from greater understanding of the role of microbial communities on the skin and in the gut.
For patients who need or want alternative approaches for treating psoriasis, balenotherapy, curcumin, indigo naturalis, fish oil supplementation, and dietary control may provide effective relief, either alone or as integrative therapy.